BREAST RADIOLOGY / ORIGINAL PAPER
Fractal analysis of tumor subregions differentiates benign from malignant breast lesions
More details
Hide details
1
Department of Radiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2
United Imaging Research Institute of Intelligent Imaging, Beijing, China
These authors had equal contribution to this work
Submission date: 2025-02-18
Final revision date: 2025-05-27
Acceptance date: 2026-01-06
Publication date: 2026-07-10
Corresponding author
Guanwu Li
Department of Radiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Rd., Shanghai 200437, China
Pol J Radiol, 2026; 91(1): 334-342
KEYWORDS
TOPICS
ABSTRACT
Purpose:
This study aimed to evaluate the effectiveness of fractal analysis in distinguishing between benign and malignant breast lesions based on tumor subregion complexity and spatial heterogeneity.
Material and methods:
Breast diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data from biopsy- and surgery-confirmed malignant (n = 75) and benign tumors (n = 32) were used to evaluate the whole-lesion heterogeneity and subregional fractal dimension (FD) using habitat imaging. Inter-reader variability in 3D region of interest definition was assessed using the Dice similarity coefficient. Receiver operating characteristic curve (ROC) analysis was conducted to assess the diagnostic performance of studied parameters in differentiating benign from malignant lesions.
Results:
The overall Dice similarity coefficient across all lesion classes was 0.86 (95% confidence interval [CI]: 0.79-0.96). The inter-reader reliability was excellent, with intraclass correlation coefficients > 0.90 for FD. Significant differences were observed between malignant and benign lesions in hypervascular cellular FD (p < 0.001) and hypovascular cellular FD (p = 0.011), but not in nonviable tissue FD (p = 0.568). Patients with malignant lesions exhibited significantly higher median heterogeneity of the whole lesion compared to those with benign lesions (p = 0.015). Among the FD features generated by habitat imaging, hypervascular cellular FD had the highest area under the ROC curve (0.925, 95% CI: 0.854-0.969), surpassing the total heterogeneity (0.671, 95% CI: 0.568-0.763). Sensitivity and specificity of 89.3% and 81.8%, respectively, were achieved in distinguishing benign from malignant lesions.
Conclusions:
Subregional FD of tumor habitats demonstrated superior diagnostic accuracy in differentiating between benign malignant breast tumors compared to the heterogeneity of the whole lesion.
REFERENCES (32)
1.
Meyer HJ, Wienke A, Surov A. Diffusion-weighted imaging of different breast cancer molecular subtypes: a systematic review and meta-analysis. Breast Care (Basel) 2022; 17: 47-54.
2.
Penn AI, Medved M, Dialani V, Pisano ED, Cole EB, Brousseau D, et al. Discrimination of benign from malignant breast lesions in dense breasts with model-based analysis of regions-of-interest using directional diffusion-weighted images. BMC Med Imaging 2020; 20: 61. DOI: 10.1186/s12880-020-00458-3.
3.
Horvat JV, Bernard-Davila B, Helbich TH, Zhang M, Morris EA, Thakur SB, et al. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer. J Magn Reson Imaging 2019; 50: 836-846.
4.
Militello C, Rundo L, Dimarco M, Orlando A, Woitek R, D’Angelo I, et al. 3D DCE-MRI radiomic analysis for malignant lesion prediction in breast cancer patients. Acad Radiol 2022; 29: 830-840.
5.
Zhou J, Zhang Y, Chang KT, Lee KE, Wang O, Li J, et al. Diagnosis of benign and malignant breast lesions on DCE-MRI by using radiomics and deep learning with consideration of peritumor tissue. J Magn Reson Imaging 2020; 51: 798-809.
6.
Kim M, Park JE, Kim HS, Kim N, Park SY, Kim YH, et al. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma. Eur Radiol 2021; 31: 6374-6383.
7.
Cho HH, Kim H, Nam SY, Lee JE, Han BK, Ko EY, et al. Measurement of perfusion heterogeneity within tumor habitats on magnetic resonance imaging and its association with prognosis in breast cancer patients. Cancers (Basel) 2022; 14: 1858. DOI: 10.3390/cancers14081858.
8.
Kazerouni AS, Hormuth DA, 2nd, Davis T, Bloom MJ, Mounho S, Rahman G, et al. Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2+ breast cancer. Cancers (Basel) 2022; 14: 1837. DOI: 10.3390/cancers14071837.
9.
Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, et al. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer 2013; 13: 390. DOI: 10.1186/1471-2407-13-390.
10.
Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 2012; 3: 573-589.
11.
Syed AK, Whisenant JG, Barnes SL, Sorace AG, Yankeelov TE. Multiparametric analysis of longitudinal quantitative MRI data to identify distinct tumor habitats in preclinical models of breast cancer. Cancers (Basel) 2020; 12: 1682. DOI: 10.3390/cancers12061682.
12.
Gillies RJ, Balagurunathan Y. Perfusion MR imaging of breast cancer: Insights using “habitat imaging”. Radiology 2018; 288: 36-37.
13.
Won SY, Lee JH, Lee N, Park YW, Ahn SS, Kim J, et al. Three-dimensional fractal dimension and lacunarity features may noninvasively predict TERT promoter mutation status in grade 2 meningiomas. PLoS One 2022; 17: e0276342.
14.
Ma J, Wang R, Yu Y, Xu X, Duan H, Yu N. Is fractal dimension a reliable imaging biomarker for the quantitative classification of an intervertebral disk? Eur Spine J 2020; 29: 1175-1180.
15.
Park YW, Kim S, Ahn SS, Han K, Kang SG, Chang JH, et al. Magnetic resonance imaging-based 3-dimensional fractal dimension and lacunarity analyses may predict the meningioma grade. Eur Radiol 2020; 30: 4615-4622.
16.
Liu S, Fan X, Zhang C, Wang Z, Li S, Wang Y, et al. MR imaging based fractal analysis for differentiating primary CNS lymphoma and glioblastoma. Eur Radiol 2019; 29: 1348-1354.
17.
Bailo M, Pecco N, Callea M, Scifo P, Gagliardi F, Presotto L, et al. Decoding the heterogeneity of malignant gliomas by PET and MRI for spatial habitat analysis of hypoxia, perfusion, and diffusion imaging: a preliminary study. Front Neurosci 2022; 16: 885291.
18.
Xu R, Yu D, Luo P, Li X, Jiang L, Chang S, et al. Do habitat MRI and fractal analysis help distinguish triple-negative breast cancer from non-triple-negative breast carcinoma. Can Assoc Radiol J 2024; 75: 584-592.
19.
Kanungo T, Mount DM, Netanyahu NS, Piatko CD, Silverman R, Wu AY. An efficient k-means clustering algorithm: analysis and implementation. IEEE Trans Pattern Anal Mach Intell 2002; 24: 881-892.
20.
Lee DH, Park JE, Kim N, Park SY, Kim YH, Cho YH, et al. Tumor habitat analysis by magnetic resonance imaging distinguishes tumor progression from radiation necrosis in brain metastases after stereotactic radiosurgery. Eur Radiol 2022; 32: 497-507.
21.
Park JE, Kim HS, Kim N, Kim YH, Kim JH, Kim E, et al. Low conductivity on electrical properties tomography demonstrates unique tumor habitats indicating progression in glioblastoma. Eur Radiol 2021; 31: 6655-6665.
22.
Czyz M, Radwan H, Li JY, Filippi CG, Tykocki T, Schulder M. Fractal analysis may improve the preoperative identification of atypical meningiomas. Neurosurgery 2017; 80: 300-308.
23.
O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 2015; 21: 249-257.
24.
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer 2015; 121: 8-16.
25.
Lee YJ, Youn IK, Kim SH, Kang BJ, Park WC, Lee A. Triple-negative breast cancer: pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence. Magn Reson Imaging 2020; 66: 36-41.
26.
Kazama T, Takahara T, Hashimoto J. Breast cancer subtypes and quantitative magnetic resonance imaging: a systemic review. Life (Basel) 2022; 12: 490. DOI: 10.3390/life12040490.
27.
Kim JJ, Kim JY, Kang HJ, Shin JK, Kang T, Lee SW, et al. Computer-aided diagnosis-generated kinetic features of breast cancer at preoperative MR imaging: association with disease-free survival of patients with primary operable invasive breast cancer. Radiology 2017; 284: 45-54.
28.
Nam SY, Ko ES, Lim Y, Han BK, Ko EY, Choi JS, et al. Preoperative dynamic breast magnetic resonance imaging kinetic features using computer-aided diagnosis: association with survival outcome and tumor aggressiveness in patients with invasive breast cancer. PLoS One 2018; 13: e0195756.
29.
Chang RF, Chen HH, Chang YC, Huang CS, Chen JH, Lo CM. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Magn Reson Imaging 2016; 34: 809-819.
30.
De Heer EC, Jalving M, Harris AL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest 2020; 130: 5074-5087.
31.
Nagasaka K, Satake H, Ishigaki S, Kawai H, Naganawa S. Histogram analysis of quantitative pharmacokinetic parameters on DCE-MRI: correlations with prognostic factors and molecular subtypes in breast cancer. Breast Cancer 2019; 26: 113-124.
32.
Bloom MJ, Song PN, Virostko J, Yankeelov TE, Sorace AG. Quantifying the effects of combination trastuzumab and radiation therapy in human epidermal growth factor receptor 2-positive breast cancer. Cancers (Basel) 2022; 14: 4234. DOI: 10.3390/cancers14174234.